全文获取类型
收费全文 | 3676篇 |
免费 | 315篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 449篇 |
妇产科学 | 14篇 |
基础医学 | 479篇 |
口腔科学 | 34篇 |
临床医学 | 129篇 |
内科学 | 73篇 |
皮肤病学 | 967篇 |
神经病学 | 362篇 |
特种医学 | 41篇 |
外科学 | 164篇 |
综合类 | 380篇 |
预防医学 | 159篇 |
眼科学 | 37篇 |
药学 | 310篇 |
2篇 | |
中国医学 | 381篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 57篇 |
2022年 | 73篇 |
2021年 | 104篇 |
2020年 | 146篇 |
2019年 | 115篇 |
2018年 | 119篇 |
2017年 | 127篇 |
2016年 | 136篇 |
2015年 | 129篇 |
2014年 | 306篇 |
2013年 | 247篇 |
2012年 | 256篇 |
2011年 | 264篇 |
2010年 | 193篇 |
2009年 | 179篇 |
2008年 | 138篇 |
2007年 | 163篇 |
2006年 | 136篇 |
2005年 | 107篇 |
2004年 | 102篇 |
2003年 | 83篇 |
2002年 | 83篇 |
2001年 | 72篇 |
2000年 | 60篇 |
1999年 | 55篇 |
1998年 | 46篇 |
1997年 | 34篇 |
1996年 | 38篇 |
1995年 | 27篇 |
1994年 | 25篇 |
1993年 | 50篇 |
1992年 | 25篇 |
1991年 | 19篇 |
1990年 | 32篇 |
1989年 | 28篇 |
1988年 | 25篇 |
1987年 | 23篇 |
1986年 | 16篇 |
1985年 | 24篇 |
1984年 | 19篇 |
1983年 | 11篇 |
1982年 | 14篇 |
1981年 | 12篇 |
1980年 | 9篇 |
1979年 | 13篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1976年 | 9篇 |
1975年 | 14篇 |
1972年 | 7篇 |
排序方式: 共有4017条查询结果,搜索用时 484 毫秒
81.
Early gut colonization by Bifidobacterium breve and B. catenulatum differentially modulates eczema risk in children at high risk of developing allergic disease 下载免费PDF全文
82.
83.
84.
Morgan Murphrey BS Samantha Casselman R.N. C.P.N.P. Kevin B. Yarbrough MD 《Pediatric dermatology》2018,35(4):e239-e240
Hand, foot, and mouth disease is a common exanthem linked to infection with several non‐polio enteroviruses. This case of an 11‐year‐old boy with an enteroviral infection limited to areas of sunburn is an atypical presentation of hand, foot, and mouth disease. Recognition of this unusual distribution will allow pediatricians and pediatric dermatologists to appropriately manage and counsel patients and parents. 相似文献
85.
Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age 下载免费PDF全文
86.
One‐year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases 下载免费PDF全文
Akiko Yagami Masutaka Furue Michinori Togawa Akihiro Saito Michihiro Hide 《The Journal of dermatology》2017,44(4):375-385
A number of second‐generation non‐sedating antihistamines are used in clinical practices over the world. However, long‐term safety and efficacy have not been proved high level evidence based medicine. We have performed an open‐label, multicenter, phase III study to evaluate the long‐term safety and efficacy of bilastine, a novel non‐sedating H1‐antihistamine for patients with chronic spontaneous urticaria (CSU) or pruritus associated with skin diseases (trial registration no. JapicCTI‐142528). Patients aged 18–74 years were treated with bilastine 20 mg once daily for up to 52 weeks. Safety and tolerability were assessed on the basis of adverse events (AE), bilastine‐related AE, laboratory tests and vital signs. Efficacy was assessed based on rash score, itch score, overall improvement and quality of life. One hundred and ninety‐eight patients enrolled, 122 of whom (61.6%) completed the 52‐week treatment period. AE were reported in 64.5% and bilastine‐related AE in 2.5% of patients throughout the 52‐week treatment period. All AE were mild to moderate in severity. AE associated with the nervous system occurred in 10 patients (5.1%) including seven patients (3.6%) with headache. Somnolence reported in two of these patients (1.0%) was related to bilastine. All efficacy variables improved during treatment with bilastine. In conclusion, long‐term treatment with bilastine 20 mg once daily for 52 weeks is safe and well tolerated in Japanese patients with CSU or pruritus associated with skin diseases. Bilastine improved disease symptoms of both conditions early in treatment, and the efficacy was maintained throughout the treatment. 相似文献
87.
88.
Discoveries in the defective molecular composition of the epidermal barrier, such as the epidermal protein filaggrin, in those with atopic eczema (or atopic dermatitis [AD]) have proved crucial in understanding this disease, but its aetiology remains to be fully elucidated. The epidermal barrier is just one interface between the microbial world and our immune system. Recent advances in molecular technology have demonstrated for the first time the true scale of the normal human microbiome and changes seen in disease states. In this review article we discuss the role of the human microbiome in the aetiology and maintenance of AD. The role of Staphylococcus aureus within the skin microbiome is examined, in addition to the role of other bacteria and fungi, identified using novel culture‐independent methods. The significant contribution of the gut microbiome and its manipulation via probiotic use is also reviewed. We emphasise that the microbiome of separate systems, including the gut, has a significant role to play in the manifestation of this cutaneous disorder. To date, there has been a lack of studies investigating whether changes to the lung microbiome may play a role in AD. An early interaction between the microbiome and immune system via multiple routes (skin–gut–lung) could feasibly affect the risk of a subsequent development of atopic diseases. When making management decisions for AD patients, clinicians must be mindful of the role of the microbiome. 相似文献
89.
90.